Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Global In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large Molecule), Indication, GLP Type (Non GLP, GLP Toxicology), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The global in vivo CRO market is expected to reach USD 7.93 billion by 2030, registering a CAGR of 8.1% during the forecast period. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.
Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.
The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different. The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.
In Vivo CRO Market Report Highlights
- The rodent-based segment held the largest revenue share of 81.8% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
- The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
- The oncology segment dominated the market in 2023, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
- The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
- The GLP toxicology segment accounted for the largest market share in 2023 owing to the increasing number of standardized studies conducted according to specific guidelines
- North America held the largest revenue share of 50% in in-vivo CRO market in 2023. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 257 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $4.59 Billion |
| Forecasted Market Value (USD) by 2030 | $7.93 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. In Vivo CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Changing regulatory landscape
3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
3.2.1.3. Rising demand for advanced products
3.2.1.4. Implementation of international standards by contract manufacturers
3.2.1.5. Rising price competition and requirement to reduce cost
3.2.1.6. Increasing complexity concerning product design and engineering
3.2.2. Market restraint analysis
3.2.2.1. Compliance issues while outsourcing
3.2.2.2. Changing scenarios in developing countries
3.2.2.3. Regulatory and legal compliance
3.2.2.4. Contractual obligation
3.3. In Vivo CRO Market Analysis Tools
Chapter 4. In Vivo CRO Market: Model Type Estimates & Trend Analysis
4.1. Model Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global In Vivo CRO Market by Model Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Rodent based
4.4.1.2. Rat models
4.4.1.3. Mice models
4.4.2. Non-rodent based
Chapter 5. In Vivo CRO Market: Modality Estimates & Trend Analysis
5.1. Modality Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global In Vivo CRO Market by Modality Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Small molecules
5.4.2. Large molecules
5.4.2.2. Cell & gene therapy
5.4.2.2.2. CAR T-cell therapies
5.4.2.2.3. CAR-NK cell therapies
5.4.2.2.4. TCR-T cell therapies
5.4.2.2.5. Other (Includes- TCR-NK, CARM, and TAC-T)
5.4.3. RNA therapy
Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis
6.1. Indication Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global In Vivo CRO Market by Indication Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Oncology
6.4.1.2. Blood cancer
6.4.1.3. Solid tumor
6.4.1.3.2. Solid tumor
6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3.2.2. Syngeneic model
6.4.1.3.2.3. Patient derived xenograft
6.4.1.3.2.4. Xenograft
6.4.2. CNS conditions
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2.2. Epilepsy
6.4.2.3. Parkinson's disease
6.4.2.4. Huntington's disease
6.4.2.5. Stroke
6.4.2.6. Muscular dystrophy
6.4.2.7. Alzheimer's disease
6.4.2.8. Traumatic brain injury
6.4.2.9. Amyotrophic lateral sclerosis (ALS)
6.4.2.10. Spinal muscular atrophy
6.4.2.11. Muscle regeneration
6.4.2.12. Other neurodevelopment disorders
6.4.3. Diabetes
6.4.4. Obesity
6.4.5. Pain management
6.4.6. Autoimmune/inflammation conditions
Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis
7.1. GLP Type Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global In Vivo CRO Market by GLP Type Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. GLP toxicology
7.4.2. Non GLP
Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, by Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
- IQVIA
- Crown Bioscience
- Taconic Biosciences
- PsychoGenics
- Evotec
- Janvier Labs
- Biocytogen Boston
- GemPharmatech
- Charles River Laboratories
- Icon Plc
- Labcorp Drug Development
- Parexel International
- SMO Clinical Research (I)
For more information about this report visit https://www.researchandmarkets.com/r/gy1axf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
